Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs

PLoS One. 2008 May 21;3(5):e2257. doi: 10.1371/journal.pone.0002257.

Abstract

It is known that physical linkage of TLR ligands and vaccine antigens significantly enhances the immunopotency of the linked antigens. We have used this approach to generate novel influenza vaccines that fuse the globular head domain of the protective hemagglutinin (HA) antigen with the potent TLR5 ligand, flagellin. These fusion proteins are efficiently expressed in standard E. coli fermentation systems and the HA moiety can be faithfully refolded to take on the native conformation of the globular head. In mouse models of influenza infection, the vaccines elicit robust antibody responses that mitigate disease and protect mice from lethal challenge. These immunologically potent vaccines can be efficiently manufactured to support pandemic response, pre-pandemic and seasonal vaccines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Viral / immunology
  • Enzyme-Linked Immunosorbent Assay
  • Epitopes / chemistry
  • Epitopes / immunology
  • Escherichia coli / genetics
  • Influenza A virus / immunology
  • Influenza Vaccines* / administration & dosage
  • Influenza Vaccines* / genetics
  • Influenza Vaccines* / immunology
  • Mice
  • Neutralization Tests
  • Protein Conformation
  • Seasons*
  • Vaccines, Synthetic* / administration & dosage
  • Vaccines, Synthetic* / genetics
  • Vaccines, Synthetic* / immunology

Substances

  • Antibodies, Viral
  • Epitopes
  • Influenza Vaccines
  • Vaccines, Synthetic